Neutralizing antibodies (NABS) and interferon beta-1B therapy of multiple sclerosis

Functional Neurology

Volumn 16, Issue 2, 2001, Pages 117-128

  Horowski, R ^a   Sturzebecher C S ^a   Kapp, J F ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Beta interferons; Multiple sclerosis; Neutralizing antibodies

Indexed keywords

ALPHA INTERFERON; BETA1 INTERFERON; HEPARIN; LENERCEPT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANTIBODY TITER; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CROSS REACTION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; PATHOGENESIS; RELAPSE; REMISSION; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES; ANTIBODY FORMATION; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; NEUTRALIZATION TESTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0034944757     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Autoimmunity is a type I interferon-deficiency syndrome corrected by type I interferon via the GALT system
2. Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-β
3. ser in healthy volunteers and its effect on serum neopterin
4. Pharmacodynamic comparison of single doses of IFN-β1a and IFN-β1b in healthy volunteers
5. Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers
6. Mechanism of action of interferon-β in multiple sclerosis
7. Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis
8. Selective inhibition of human glia inducible nitric oxide synthase by interferon-beta: Implications for multiple sclerosis
9. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-1b
10. Changes of serum sICAM-1 and MMP-9 induced by rIFNβ-1b treatment in relapsing-remitting MS
11. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis
12. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years
13. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis
14. Correlation of the appearance of anti-interferon antibodies during treatment and diminution of efficacy: Summary of an international workshop on anti-interferon antibodies
15. Development of antibodies to interferon beta in patients: Technical and biological aspects
16. Autoimmunity in multiple sclerosis: Study of a wide spectrum of autoantibodies
17. Interferons in multiple sclerosis
18. Anti-TNF therapy inhibits fever in cerebral malaria
19. Antibodies to commercially available interferon-beta molecules in multiple sclerosis patients treated with natural interferon-beta
20. Neutralising and binding anti-interferon-β-1b (IFN-β-1b) antibodies during IFN-β-1b treatment of multiple sclerosis
21. The nature of neutralization reaction between effector protein and monoclonal antibody: A quantitative study of neutralization characteristics of anti-interferon antibodies
22. The expression of potency of neutralizing antibodies for interferons and other cytokines
23. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis
24. Incidence and significance of neutralizing antibodies to interferon-beta 1a in multiple sclerosis
25. Incidence of antibodies to interferon-β in patients treated with recombinant human interferon-β1a from mammalian cells
26. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive
27. Antibodies that neutralize human beta interferon biologic activity recognize a linear epitope: Analysis by synthetic peptide mapping
28. Assays for antibodies to human interferon-alpha: The need for standardization
29. Quantitation and characterization of multiple sclerosis patient antibodies to interferon-β
30. A novel sensitive and selective bioassay for human type I interferons
31. Guidelines for physicians with patients on IFNβ-1b. The use of an assay for neutralizing antibodies (NAB)
32. Differential neutralizing activity of human antibodies in interferon antiviral and natural killer cell bioassays
33. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies
34. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b
35. Comparison of ELISA with MxA assay for the detection of antibodies to interferon-beta and results of long-term follow up
36. Loss of interferon antibodies during prolonged continuous interferon-alpha 2a therapy in hairy cell leukemia
37. Association between neutralizing antibodies to interferon beta and contrast enhancing lesions in multiple sclerosis patients
38. Neutralizing antibodies in Betaseron-treated multiple sclerosis patients and in vitro immune function before treatment
39. Third Symposium of the MS-Forum, Istanbul, Turkey: Reviewing Multiple Sclerosis
40. Anticytokine antibodies in beta interferon-treated MS patients and the need for testing
41. Randomised double-blind controlled study of interferon-β 1a in relapsing-remitting multiple sclerosis: Clinical results
42. Evidence of interferon β-1a dose response in relapsing-remitting MS
43. Neutralizing antibodies: Are they an issue?
44. Methylprednisolone in association with IFNβ-1b to suppress the development of NABs in relapsing-remitting multiple sclerosis
45. Antibodies to beta-interferons in multiple sclerosis - Can we neutralize the controversy?